Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$49.84 - $70.47 $79,744 - $112,752
1,600 Added 35.56%
6,100 $386,000
Q2 2024

Aug 09, 2024

BUY
$47.39 - $80.2 $213,255 - $360,900
4,500 New
4,500 $238,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Tcg Advisory Services, LLC Portfolio

Follow Tcg Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tcg Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tcg Advisory Services, LLC with notifications on news.